Aeglea BioTherapeutics is a holding company. Through its subsidiaries, Co. is a biotechnology company developing human enzyme therapeutics for people with rare metabolic diseases. Co.'s development programs include: Pegzilarginase in Arginase 1 Deficiency, which is a recombinant human Arginase 1 that enzymatically degrades the amino acid arginine and improves the stability and arginine-degrading activity of the enzyme in human plasma; and AGLE-177 in Homocystinuria, which is a PEGylated, or polyethylene glycol modified, human enzyme engineered to degrade free homocysteine and homocystine. Co.'s preclinical pipeline includes cystinuria program to reduce plasma cystine and cysteine levels. The AGLE stock yearly return is shown above.
The yearly return on the AGLE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2022 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the AGLE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|